Novel Hybrid Molecules of Cannabidiol and Nonsteroidal Anti-Inflammatory Drugs With Anti-Glioblastoma Potential – a Preliminary Study
Acta Poloniae Pharmaceutica - Drug Research · 21.05.2026 · 82 (6) · 909-930
DOI: 10.32383/appdr/220420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 21.05.2026. Verfasst von Anna Rybarczyk und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system. Among novel therapeutic strategies, the development of two‑drug hybrid molecules -single entities composed of two pharmacophores - has emerged as a promising approach. Principal component analysis of structural and physicochemical descriptors of cannabinoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and CBD–NSAID hybrids revealed distinct physicochemical profiles for each group, suggesting that the hybrids may possess new and potentially advantageous functionalities. Thus, this study aimed to synthesize and biologically characterize five novel hybrid molecules composed of cannabidiol (CBD) and selected NSAIDs: ibuprofen (IBU), ketoprofen (KET), naproxen (NAP), indomethacin (INDO), and sulindac (SUL). Cytotoxicity analyses (MTT assay) in GBM T98G and U-138 MG cells, as well as non‑cancerous MRC‑5 cells, demonstrated potent anti‑GBM activity of the hybrids - particularly CBD–IBU - together with a more favorable toxicity profile toward normal cells. Using the Luminex MAGPIX® multiplex immunoassay system, we observed that the hybrids modulate key GBM‑related signaling molecules, including NF‑κB, STAT3, STAT5, AKT, p70, p70S6K, JNK, ERK1/2, p38, and CREB. Additionally, in silico docking studies revealed strong predicted binding of the hybrids - especially CBD–SUL - to the Keap1 Kelch domain. In conclusion, our study provides preliminary evidence supporting the anti‑GBM potential of these novel CBD–NSAID hybrid molecules. However, further mechanistic studies and in‑depth in vivo evaluation are needed to fully validate their therapeutic applicability.
Zitieren
APA
Rybarczyk, A., Kossakowski, K., Majchrzak-Celińska, A., Pawełczyk, A., Kujawski, J., & Krajka-Kuźniak, V. (2026). Novel Hybrid Molecules of Cannabidiol and Nonsteroidal Anti-Inflammatory Drugs With Anti-Glioblastoma Potential – a Preliminary Study. Acta Poloniae Pharmaceutica - Drug Research, 82(6), 909-930. https://doi.org/10.32383/appdr/220420
Vancouver
Rybarczyk A, Kossakowski K, Majchrzak-Celińska A, Pawełczyk A, Kujawski J, Krajka-Kuźniak V. Novel Hybrid Molecules of Cannabidiol and Nonsteroidal Anti-Inflammatory Drugs With Anti-Glioblastoma Potential – a Preliminary Study. Acta Poloniae Pharmaceutica - Drug Research. 2026;82(6):909-930. doi:10.32383/appdr/220420
BibTeX
@article{Rybarczyk2026,
author = {Rybarczyk, Anna and Kossakowski, Kacper and Majchrzak-Celińska, Aleksandra and Pawełczyk, Anna and Kujawski, Jacek and Krajka-Kuźniak, Violetta},
title = {Novel Hybrid Molecules of Cannabidiol and Nonsteroidal Anti-Inflammatory Drugs With Anti-Glioblastoma Potential – a Preliminary Study},
journal = {Acta Poloniae Pharmaceutica - Drug Research},
year = {2026},
volume = {82},
number = {6},
pages = {909--930},
doi = {10.32383/appdr/220420}
}
EUVIMED